Birchview Capital’s Albireo Pharma Inc ALBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-117,000
| Closed | -$2.53M | – | 58 |
|
|
2022
Q4 | $2.53M | Hold |
117,000
| – | – | 1.79% | 12 |
|
|
2022
Q3 | $2.27M | Buy |
117,000
+4,000
| +4% | +$82.7K | 1.59% | 13 |
|
|
2022
Q2 | $2.24M | Hold |
113,000
| – | – | 1.63% | 12 |
|
|
2022
Q1 | $3.37M | Hold |
113,000
| – | – | 2.43% | 7 |
|
|
2021
Q4 | $2.63M | Hold |
113,000
| – | – | 1.7% | 11 |
|
|
2021
Q3 | $3.53M | Buy |
113,000
+2,000
| +2% | +$61.9K | 2.4% | 8 |
|
|
2021
Q2 | $3.9M | Hold |
111,000
| – | – | 2.34% | 8 |
|
|
2021
Q1 | $3.91M | Buy |
111,000
+19,000
| +21% | +$701K | 2.32% | 8 |
|
|
2020
Q4 | $3.45M | Buy |
92,000
+34,000
| +59% | +$1.24M | 1.99% | 9 |
|
|
2020
Q3 | $1.94M | Buy |
58,000
+10,000
| +21% | +$291K | 1.29% | 14 |
|
|
2020
Q2 | $1.27M | Hold |
48,000
| – | – | 0.77% | 20 |
|
|
2020
Q1 | $786K | Hold |
48,000
| – | – | 0.7% | 20 |
|
|
2019
Q4 | $1.22M | Buy |
48,000
+10,000
| +26% | +$200K | 0.89% | 18 |
|
|
2019
Q3 | $760K | Hold |
38,000
| – | – | 0.51% | 19 |
|
|
2019
Q2 | $1.23M | Hold |
38,000
| – | – | 0.75% | 13 |
|
|
2019
Q1 | $1.22M | Hold |
38,000
| – | – | 0.77% | 12 |
|
|
2018
Q4 | $932K | Hold |
38,000
| – | – | 0.88% | 13 |
|
|
2018
Q3 | $1.25M | Hold |
38,000
| – | – | 0.81% | 16 |
|
|
2018
Q2 | $1.35M | Buy |
38,000
+14,000
| +58% | +$453K | 0.92% | 13 |
|
|
2018
Q1 | $782K | Buy |
+24,000
| New | +$808K | 0.52% | 17 |
|
Other funds holding ALBO
Birchview Capital's ALBO Position: Q1 2023 in Review
Birchview Capital sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 117,000 shares — an estimated $2.53M sold.
Birchview Capital first reported a position in ALBO in Q1 2018 and held it in 20 quarters. The position peaked at $3.91M in Q1 2021. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.
- Birchview Capital reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
- Birchview Capital sold 117,000 Albireo Pharma Inc shares in Q1 2023, an estimated $2.53M.
- Birchview Capital first reported a position in Albireo Pharma Inc in Q1 2018 and held it in 20 quarters.
- Birchview Capital's Albireo Pharma Inc position peaked at $3.91M in Q1 2021.
- 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.
Based on Birchview Capital's 13F filing for Q1 2023, filed 12 May 2023.